Glancy
Prongay & Murray LLP (“GPM”) reminds investors of the class
action lawsuit on behalf of investors of Clovis Oncology, Inc. ("Clovis"
or the "Company") (NYSE:CLVS) between October 31, 2013 and November 15,
2015, inclusive (the "Class Period"). Injured investors are encouraged
to contact Lesley Portnoy of GPM at 310-201-9150 to discuss their legal
rights prior to the January 19, 2016 lead plaintiff deadline.
Clovis is a biopharmaceutical company that focuses on acquiring,
developing, and commercializing innovative anti-cancer agents in the
United States, Europe and additional international markets.
Throughout the Class Period, Defendants made false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants made false and/or misleading statements and/or failed to
disclose: (1) that the New Drug Application (“NDA”) that Clovis
submitted to the FDA for rociletinib contained immature data sets based
on both unconfirmed response rates and confirmed response rates; (2)
that Clovis’ Breakthrough Therapy designation submission contained
immature data set based primarily on unconfirmed responses; (3) that
Clovis presented interim data publicly and at medical meetings that
included a data set based primarily on unconfirmed responses; (4) that
as the efficacy data matured, the number of patients with an unconfirmed
response who converted to a confirmed response was lower than expected;
(5) that, as a result of the foregoing, Clovis’ NDA was likely to be
delayed and/or rejected by the FDA; and (6) that, as a result of the
foregoing, the Defendants’ statements about Clovis’ business,
operations, and prospects, were false and misleading and/or lacked a
reasonable basis.
Clovis investors have until January 19, 2016 to move the Court to
appoint you as lead plaintiff if you meet certain legal requirements. If
you have information or would like to learn more about these claims, or
have any questions concerning this announcement or your rights or
interests with respect to these matters, please contact Lesley Portnoy,
of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California
90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151216005884/en/
Copyright Business Wire 2015